BELLINGS

Stock Market Today, Aug. 19: Moderna Skyrockets 177% on Positive Phase 3 Melanoma Data

Moderna (NASDAQ:MRNA), an mRNA medicine and preventive vaccines provider, closed at $174.38, up 176.97%. Shares surged after Moderna and Merck reported positive Phase 3 melanoma data. Investors are watching for FDA plans and further developments for the treatment. Trading volume

Moderna (NASDAQ:MRNA), an mRNA medicine and preventive vaccines provider, closed at $174.38, up 176.97%. Shares surged after Moderna and Merck reported positive Phase 3 melanoma data. Investors are watching for FDA plans and further developments for the treatment. Trading volume

BELLINGS Intelligence Score: 12

Why it matters

Moderna's stock surge on positive Phase 3 melanoma data is notable company-specific news but does not directly affect credit markets or broader financial conditions relevant to credit professionals.

Sources